



# BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. : 0731-2723016, 4066516 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel. : 0731-2426700, 2420926, 2524003, Fax : 0731-2420926 • CIN : L24233MP1985PLC002709

Date:30/05/2016

To,  
The Company Secretary,  
Corporate Compliance Department  
The National Stock Exchange of India Limited  
Bandra Kurla Complex, Mumbai

To,  
The Company Secretary  
Corporate Compliance Department  
BSE Limited  
Dalal Street, P.J. Tower, Mumbai

**Sub: Approval of Annual Audited Financial Result for the quarter/year ended on 31<sup>st</sup> March,2016 along with Auditors Report thereon and declaration as per second proviso to the Regulation 33 (d) of LODR,2015**

**Scripe Code: 524396; Sripe Id: BIOFILCHEM**

Dear Sir/Madam

With reference to the above-mentioned subject in meeting of the Board of the Directors of the Company held on today, has approved the Audited Financial Result/statement for the quarter/year ended on 31<sup>st</sup> March,2016 along with Auditors Report thereon and declaration as per second proviso to the Regulation 33 (d) of LODR,2015

This is further to inform you that the Board meeting was commenced at 7.30 p.m. and concluded at 9.30 p.m.

Copy of audited financial result along with Auditors' report in prescribed format is enclosed with this letter and copy of the same is also available on website of the Company. i.e [www.biofilgroup.net](http://www.biofilgroup.net)

Extract of the financial result shall be published in Hindi and English news papers.

This is for your information and record.

Thanking you,

Yours Faithfully,  
For Biofil Chemicals and Pharmaceuticals Limited

  
Shikha Khilwani  
Company Secretary & Compliance Officer



**S.N. Gadiya & Co.**  
(Chartered Accountants)

**Satya Narayan Gadiya**  
F.C.A., B. Com.  
Mob. : 9301503126

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To  
The Board of Directors  
Biofil Chemicals and Pharmaceuticals Limited

We have audited the quarterly financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the quarter ended on 31<sup>st</sup> March, 2016 and the year to date results for the period 1<sup>st</sup> April, 2015 to 31<sup>st</sup> March, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India<sup>1</sup>, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarter financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended on 31<sup>st</sup> March 2016 as well as the year to date results for the period from 1<sup>st</sup> April 2015 to 31<sup>st</sup> March 2016.

Place: Indore  
Date: 30.05.2016



For S.N. Gadiya & Co  
Chartered Accountants  
(Registration No 002052C)

S.N. Gadiya (Proprietor)  
M No.071229





# BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. 0731-2723016, 4066516 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel 0731-2426700, 2420926, 2524003, Fax : 0731-2420926 • CIN : L24233MP1985PLC002709

Date:30/05/2016

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
---	--

Script Code: 524396; Sripid Id: BIOFILCHEM

Sub.; Submission of declaration as per Second proviso to the Regulation 33(3)(d) of the SEBI (LODR) Regulation, 2015 for the Annual Audited Financial Results for the year ended 31<sup>st</sup> March, 2016

Dear Sir,

I hereby submit the following declaration regarding unmodified Auditors Report on the audited Financial Results/Statements for the year 31<sup>st</sup> March, 2016 as audited by the Auditor of the Company.

Pursuant to SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, and amendments made therein vide SEBI Circular No SEBI/LAD-NRO/GN/2016-17 dated 25<sup>th</sup> May, 2016 and further amendment dated 27<sup>th</sup> May, 2016, I, the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Financial Statements of M/s Biofil Chemicals and Pharmaceuticals Limited for the financial year ended on 31.03.2016, the Auditor does not expressed any Modified Opinion(s)/ Audit Qualification(s)/ or other Reservation(s) and accordingly the the statement on impact of audit qualifications is not required to be given.

You are requested to please consider and take on record the same.

For Biofil Chemicals and Pharmaceuticals Ltd.

Ramesh Shah  
Managing Director





**Audited Financial Results of Quarter and Year Ended of March . 2016**

**31-03-2016 of M/s. Biofil Chemicals & Pharmaceuticals Limited**


**11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)**

**CIN L24233MP1985PLC002709**

**AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March , 2016**

( Amount in Lakhs)

Statement of Standalone Financial Results for the Quarter & Year ended 31st March 2016						
Particulars	For the Quarter ended March 31 2016	For the quarter ended December 31 2015	For the Quarter ended March 31 2015	Audited for the year ended March 31 2016	Audited for the year Ended March 31 2015	
	Audited	Reviewed	Audited	Audited	Audited	
<b>1 Income from operations</b>						
(a) Net sales/ income from operations (Net of Excise duty)	287.54	680.54	263.42	1085.65	456.45	
(b) Other operating income	234.59	8.90	114.09	251.65	129.71	
<b>Total income from operations (net)</b>	<b>522.13</b>	<b>689.44</b>	<b>377.51</b>	<b>1337.30</b>	<b>586.16</b>	
<b>2 Expenses</b>						
(a) Cost of materials consumed	47.26	23.38	52.78	121.34	109.86	
(b) Purchases of stock-in-trade	1.90	899.85	198.13	932.53	276.27	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	285.07	(280.52)	11.21	0.58	1.95	
(d) Employee benefits expense	27.97	8.17	27.70	48.23	49.71	
(e) Depreciation and amortisation expense	6.70	6.26	5.04	26.49	25.07	
(f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	85.45	20.27	52.17	127.42	75.00	
<b>Total expenses</b>	<b>454.34</b>	<b>677.41</b>	<b>347.03</b>	<b>1256.58</b>	<b>537.86</b>	
<b>3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>67.78</b>	<b>12.02</b>	<b>30.48</b>	<b>80.71</b>	<b>48.30</b>	
<b>4 Other income</b>	<b>7.98</b>	<b>3.86</b>	<b>25.04</b>	<b>32.55</b>	<b>46.19</b>	
<b>5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>75.76</b>	<b>15.89</b>	<b>55.52</b>	<b>113.26</b>	<b>94.49</b>	
<b>6 Finance costs</b>	<b>3.97</b>	<b>3.75</b>	<b>4.13</b>	<b>15.19</b>	<b>20.95</b>	
<b>7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)</b>	<b>71.79</b>	<b>12.14</b>	<b>51.40</b>	<b>98.07</b>	<b>73.54</b>	
<b>8 Exceptional items</b>	<b>1.12</b>		<b>0.81</b>	<b>1.12</b>	<b>0.81</b>	
<b>9 Profit / (Loss) from ordinary activities before tax (7 + 8)</b>	<b>70.67</b>	<b>12.14</b>	<b>50.58</b>	<b>96.95</b>	<b>72.73</b>	
<b>10 Tax expense</b>	<b>18.69</b>		<b>14.01</b>	<b>18.69</b>	<b>14.01</b>	
<b>11 Net Profit / (Loss) from ordinary activities after tax (9 + 10)</b>	<b>51.98</b>	<b>12.14</b>	<b>36.57</b>	<b>78.26</b>	<b>58.72</b>	
<b>12 Extraordinary items (net of tax Rs expense _____ lakhs)</b>					<b>0.00</b>	
<b>13 Net profit/(loss) for the period (11+12)</b>	<b>51.98</b>	<b>12.14</b>	<b>36.57</b>	<b>78.26</b>	<b>58.72</b>	
<b>14 Share of Profit/Loss of Associates</b>	-	-	-	-	-	
<b>15 Minority Interest</b>	-	-	-	-	-	
<b>16 Net Profit/(loss) after taxes, minority interest and share of profit/(Loss) of associates after tax (13+14+15)</b>	<b>51.98</b>	<b>12.14</b>	<b>36.57</b>	<b>78.26</b>	<b>58.72</b>	
<b>17 Paid up Equity Share Capital (Face value of the share shall be indicated )</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	
<b>18 Reserve excluding Revaluation Reserve as per the Balance Sheet of previous accounting year</b>				<b>-913.35</b>	<b>-1162.99</b>	
<b>19.i Earnings per share (before extraordinary items)</b>						
<b>(of Rs. 10/- each) (not annualised):</b>						
(a) Basic	0.32	0.07	0.22	0.48	0.36	
(b) Diluted	0.32	0.07	0.22	0.48	0.36	
<b>19.ii Earnings per share (after extraordinary items)</b>						
<b>(of Rs. 10/- each) (not annualised):</b>						
(a) Basic	0.32	0.07	0.22	0.48	0.36	
(b) Diluted	0.32	0.07	0.22	0.48	0.36	



• The above audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 30<sup>th</sup> Day of May , 2016

The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figure up to third quarter of the current financial year

• Previous year period's/year's figures have been regrouped wherever necessary to conform to the current period's classification.

• The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

1. Pharma Product
2. Chemicals Division
3. Plastic Division

The aforesaid audited financial Results will be uploaded on the Company's website [www.biofilgroup.net](http://www.biofilgroup.net) and will also be available on the websites of the Stock exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) for the benefit of shareholders and investors

Date 30/05/2016  
Place indore

FOR Biofil Chemicals & Pharmaceuticals Limited

  
RAMESH SHAH  
MANAGING DIRECTOR  
(DIN : 00028819)



**BIOFIL CHEMICALS & PHARMACEUTICALS LTD.**  
**CIN NO. L24233MP1985PLC002709**

**Segmentwise Revenue, Results an Capital Employed for year ended 31st March 2016**

S.No.	Segment Revenue	Quarter Ended			Year Ended	
		March 31 ,	December 31,	March 31 ,	31 March	31 March
		2016	2015	2015	2016	2015
		Audited	Reviewed	Audited	Audited	Audited
1	<b>Segment Revenue</b>					
	Pharma Unit	479.52	653.77	338.10	1160.00	418.30
	Chemicals Division	33.01	20.64	39.35	134.524	130.45
	Plastic Division	6.51	6.13	15.68	22.624	37.40
	Other	11.07	12.76	15.94	52.696	46.19
	<b>Gross Turnover</b>	<b>530.12</b>	<b>693.30</b>	<b>409.07</b>	<b>1369.85</b>	<b>632.34</b>
2	<b>Segment Results</b>					
	Pharma Unit	139.00	7.11	88.14	148.07	102.66
	Chemicals Division	(63.77)	6.79	(35.30)	(32.02)	(10.32)
	Plastic Division	(4.10)	1.99	6.93	(7.39)	(0.11)
	Other	2.29	0.00	(4.70)	2.29	1.82
	<b>Total Segment Profit Before Tax</b>	<b>73.42</b>	<b>15.89</b>	<b>55.08</b>	<b>110.95</b>	<b>94.06</b>
	Interest Income	2.18	0.00	0.30	2.18	0.30
	Interest Expenses	3.81	3.75	3.99	15.06	20.81
	Other Unallocable Income net of Expenditure					
	<b>Profit Before Tax</b>	<b>71.79</b>	<b>12.14</b>	<b>51.38</b>	<b>98.07</b>	<b>73.54</b>
	Provision for current tax	18.69	0.00	14.01	18.69	14.01
	Item Related Earlier Year	1.12		0.81	1.12	0.81
	<b>Profit After Tax</b>	<b>51.98</b>	<b>12.14</b>	<b>36.56</b>	<b>78.26</b>	<b>58.72</b>
3	<b>Capital Employed</b>					
	<b>(Segment Assets- Segment Liabilities)</b>					
	Pharma Unit	396.16	157.92	146.02	396.16	146.02
	Chemicals Division	722.235	720.79	727.16	722.23	727.16
	Plastic Division	(46.410)	(49.22)	(45.72)	(46.41)	(45.72)
	Other	-	-	-	-	-
	<b>Total Capital Employed</b>	<b>1071.99</b>	<b>829.49</b>	<b>827.46</b>	<b>1071.99</b>	<b>827.46</b>

DATE : 30-05-2016  
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

**RAMESH SHAH**  
**MANAGING DIRECTOR**  
DIN: 00028819

**BIOFIL CHEMICALS & PHARMACEUTICALS Ltd.**  
**AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 31-03-2016**  
**CIN NO. L24233MP1985PLC002709**

(In Rs.)

Standalone / Consolidated Statement of Assets and Liabilities		standlone	
		31, March 2016	31, March 2015
	Particulars	Audited	Audited
<b>A</b>	<b>EQUITY &amp; LIABILITIES</b>		
<b>1</b>	<b>Shareholders' funds</b>		
	(a) Share Capital	162738000	162738000
	(b) Reserves & Surplus	-53670404	-78590326
	(c) Money received against share warrants		
	<b>Sub-total - Shareholders' funds</b>	<b>109067597</b>	<b>84147674</b>
<b>2</b>	<b>Share application money pending allotment</b>		
<b>3</b>	<b>Minority interest *</b>		
<b>4</b>	<b>Non-current liabilities</b>		
	(a) Long-term borrowings		
	(b) Deferred tax liabilities (net)		
	(c) Other long-term liabilities		
	(d) Long-term provisions		
	<b>Sub-total Non-current liabilities</b>		
<b>5</b>	<b>Current liabilities</b>		
	(a) Short-term borrowings	13699750	29800596
	(b) Trade payables	115918453	21109002
	(c) Other current liabilities	-	-
	(d) Short-term provisions	2633609	2505553
	<b>Sub-total Current liabilities</b>	<b>132251812</b>	<b>53415151</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>241319409</b>	<b>137562825</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Fixed assets		
	Tangible Assests	89755340	90576538
	(b) Goodwill on consolidation *		
	(c) Non-current investments		
	(d) Deferred tax assets (net)		
	(e) Long-term loans and advances		
	(f) Other non-current assets		
	<b>Sub-total - Non-current assets</b>	<b>89755340</b>	<b>90576538</b>
<b>2</b>	<b>Current assets</b>		
	Current investments		
	Inventories	960220	1664534
	Trade receivables	139846275	36512233
	Cash and cash equivalents	1808146	1276152
	Short-term loans and advances	5209803	5279724
	Other current assets	3739625	2253644
	<b>Sub-total - Current assets</b>	<b>151564069</b>	<b>46986287</b>
	<b>TOTAL - ASSETS</b>	<b>241319409</b>	<b>137562825</b>

DATE : 30/05/2016  
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

  
**RAMESH SHAH**  
MANAGING DIRECTOR  
DIN: 00028819